Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Enocitabine 是一种核苷类似物,抑制 DNA 复制剂。Enocitabine 抑制人巨细胞病毒的复制,显示出抗白血病和抗病毒活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,210 | 现货 | ||
5 mg | ¥ 3,230 | 现货 | ||
10 mg | ¥ 4,730 | 现货 | ||
25 mg | ¥ 7,480 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,600 | 4-6周 |
产品描述 | Enocitabine is a nucleoside analog. Enocitabine inhibits the replication of human cytomegalovirus(HCMV) and it also has antileukemic and antiviral activities. Enocitabine is also a potent DNA replication inhibitor and a DNA chain terminator. |
体外活性 | The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells [2]. In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed [3]. |
分子量 | 565.78 |
分子式 | C31H55N3O6 |
CAS No. | 55726-47-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 2 mg/mL (3.53 mM), Sonification and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7675 mL | 8.8374 mL | 17.6747 mL | 44.1868 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Enocitabine 55726-47-1 Cell Cycle/Checkpoint DNA Damage/DNA Repair Microbiology/Virology Proteases/Proteasome HCV Protease Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Inhibitor CMV inhibit Sunrabin Cytomegalovirus AML acute myelogenous leukaemia inhibitor